Adenocarcinoma, Sebaceous
"Adenocarcinoma, Sebaceous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant tumor composed of cells showing differentiation toward sebaceous epithelium. The tumor is solitary, firm, somewhat raised, more or less translucent, and covered with normal or slightly verrucose epidermis. It may be yellow or orange. The face and scalp are the commonest sites. The growth can be slow or rapid but metastasis is uncommon. Surgery cures most of the cases. (From Rook et al., Textbook of Dermatology, 4th ed, pp2403-4)
MeSH Number(s)
C04.557.470.200.025.105
C04.557.470.550.105
Concept/Terms
Adenocarcinoma, Sebaceous- Adenocarcinoma, Sebaceous
- Adenocarcinomas, Sebaceous
- Sebaceous Adenocarcinoma
- Sebaceous Adenocarcinomas
Below are MeSH descriptors whose meaning is more general than "Adenocarcinoma, Sebaceous".
Below are MeSH descriptors whose meaning is more specific than "Adenocarcinoma, Sebaceous".
This graph shows the total number of publications written about "Adenocarcinoma, Sebaceous" by people in Harvard Catalyst Profiles by year, and whether "Adenocarcinoma, Sebaceous" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1999 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
Below are the most recent publications written about "Adenocarcinoma, Sebaceous" by people in Profiles.
-
Infiltrative Sebaceous Carcinoma Presenting as a "Tumor Tarsorrhaphy". Ophthalmic Plast Reconstr Surg. 2022 Jan-Feb 01; 38(1):e35.
-
Sebaceous Epithelial-Myoepithelial Carcinoma With Aggressive Behavior and Evidence of Preexisting Pleomorphic Adenoma. Int J Surg Pathol. 2021 Aug; 29(5):524-528.
-
High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors. Am J Ophthalmol. 2020 12; 220:128-139.
-
Sebaceous carcinoma: evidence-based clinical practice guidelines. Lancet Oncol. 2019 12; 20(12):e699-e714.
-
Demonstration of a Borst-Jadassohn-Like Phenomenon in Sebaceous Carcinoma of the Eyelid. Ophthalmic Plast Reconstr Surg. 2017 May/Jun; 33(3S Suppl 1):S63-S66.
-
p16 Expression Is Not a Surrogate Marker for High-Risk Human Papillomavirus Infection in Periocular Sebaceous Carcinoma. Am J Ophthalmol. 2016 Oct; 170:168-175.
-
Updates on the Molecular Pathology of Selected Ocular and Ocular Adnexal Tumors: Potential Targets for Future Therapy. Semin Ophthalmol. 2016; 31(1-2):188-96.
-
Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target. J Cancer Res Clin Oncol. 2016 Jan; 142(1):125-33.
-
Presumed primary papillary sebaceous carcinoma of the palpebral conjunctiva. JAMA Ophthalmol. 2015 May; 133(5):612-4.
-
Cancer Stem Cell Markers in Eyelid Sebaceous Gland Carcinoma: High Expression of ALDH1, CD133, and ABCG2 Correlates With Poor Prognosis. Invest Ophthalmol Vis Sci. 2015 Feb 24; 56(3):1813-9.